Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Guselkumab: Short‐term effectiveness and safety in real clinical practice

(2020) Lourdes Rodriguez Fernandez‐Freire et al.   Dermatologic Therapy

Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study

(2020) A.‐C. Fougerousse et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis

(2019) A. Mourad et al.   BRITISH JOURNAL OF DERMATOLOGY

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience

(2019) M. Galluzzo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A safety evaluation of guselkumab for the treatment of psoriasis

(2018) M. Galluzzo et al.   Expert Opinion On Drug Safety

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions

(2018) Peter Foley et al.   JAMA Dermatology

Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials

(2018)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment Approaches to Moderate to Severe Psoriasis

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

(2017) P. Gisondi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort

(2016) J. Zweegers et al.   BRITISH JOURNAL OF DERMATOLOGY

Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity

(2016) Ann Sophie Lønnberg et al.   JAMA Dermatology

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

(2013) J.M. Carrascosa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis

(2012) J. Romaní et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA

(2012) Rosa María Fernández-Torres et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland

(2011) P.M. Laws et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre

(2010) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre

(2008) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

(2008) Luigi Naldi et al.   DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET